Avacta Group Plc operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Avacta Group Plc with three other
companies in this sector in the United Kingdom:
Genedrive PLC
(2018
sales of £1.94 million [US$2.48 million]
of which 100%
was Diagnostics Segment),
Midatech Pharma PLC
(£1.94 million [US$2.48 million]
of which 100%
was Pipeline R&D), and
Fusion Antibodies PLC
(£2.69 million [US$3.44 million]
).
Sales Analysis.
Avacta Group Plc reported sales of £2.76 million (US$3.53 million)
for the
fiscal
year ending
July of 2018.
This
represents
a very small
increase of 1.0%
versus 2017, when the company's sales were £2.74 million.
This was the third consecutive year of growth at Avacta Group Plc.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Avacta Group Plc had sales
of £2.70 million.
Sales of Life Sciences saw an increase
that was more than double the company's growth rate: sales were up
4.0% in 2018, from
£1.15 million to £1.19 million.
Not all segments of Avacta Group Plc experienced an increase in sales in 2018:
sales of Animal Health fell 1.1% to £1.57 million.